Inovio Pharmaceuticals (INO) Expected to Announce Earnings on Wednesday

Inovio Pharmaceuticals (NASDAQ:INO) will likely be announcing its earnings results before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.92) per share and revenue of $0.03 million for the quarter.

Inovio Pharmaceuticals Stock Down 7.1 %

Shares of INO opened at $1.84 on Tuesday. The firm has a market cap of $48.02 million, a price-to-earnings ratio of -0.88 and a beta of 0.89. The business’s 50 day moving average is $2.02 and its two-hundred day moving average is $4.24. Inovio Pharmaceuticals has a 52-week low of $1.74 and a 52-week high of $14.75.

Wall Street Analyst Weigh In

INO has been the topic of a number of research analyst reports. Royal Bank of Canada reduced their price objective on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Friday, November 15th. JMP Securities reiterated a “market outperform” rating and issued a $18.00 price target on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th. HC Wainwright cut their price objective on Inovio Pharmaceuticals from $5.00 to $3.00 and set a “neutral” rating on the stock in a research note on Monday, January 13th. Finally, Oppenheimer reduced their target price on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a report on Monday, November 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $12.40.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.